MWP
XLRN

Meridian Wealth Partners’s Acceleron Pharma XLRN Stock Holding History

Meridian Wealth Partners’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-127
Closed -$18K – 1460
2021
Q1 		$18K Buy
+127
New +$16.4K 0.01% 307

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Meridian Wealth Partners's XLRN Position: Q2 2021 in Review

Meridian Wealth Partners sold out of Acceleron Pharma (XLRN) in Q2 2021, closing a stake of 127 shares — an estimated $18K sold.

Meridian Wealth Partners first reported a position in XLRN in Q1 2021 and held it in 1 quarter. The position peaked at $18K in Q1 2021. 271 funds tracked by Wall St. Rank hold XLRN as of Q2 2021.

  • Meridian Wealth Partners reported no remaining Acceleron Pharma position as of Q2 2021 after selling out during the quarter.
  • Meridian Wealth Partners sold 127 Acceleron Pharma shares in Q2 2021, an estimated $18K.
  • Meridian Wealth Partners first reported a position in Acceleron Pharma in Q1 2021 and held it in 1 quarter.
  • Meridian Wealth Partners's Acceleron Pharma position peaked at $18K in Q1 2021.
  • 271 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2021.

Based on Meridian Wealth Partners's 13F filing for Q2 2021, filed 12 Aug 2021.